MET is unique in that 3 different genomic states can lead to clinically relevant oncogenesis: amplification, mutation, and fusion.5 A recent case report described a patient with ICC harboring a MET fusion who achieved a response to crizotinib.6 In this case report, we highlight a patient with ICC harboring a novel RBPMS-MET fusion who experienced a dramatic response to crizotinib. The gene discussed is RBPMS; the disease is intrahepatic cholangiocarcinoma.